abstract |
The present invention provides four known mammalian JAK kinases (JAK1, JAK2, JAK3 and TYK2) and compounds that inhibit PDK1. The present invention also provides compositions comprising such inhibitory compounds and the activity of JAK1, JAK2, JAK3 TYK2 and PDK1 by administering the compounds to patients in need of treatment for myeloproliferative syndrome or cancer. Provide a method of inhibiting |